Musculoskeletal Costs: Back, Joint, and Spine Claims and the Compounding Problem Most Plans Ignore

The MRI costs $1,500. The orthopedic consultation costs $400. The physical therapy course costs $2,400 over twelve sessions. The epidural injection costs $2,800. None of these claims appears in the high-cost claimant report. None triggers stop loss review. None catches the plan sponsor’s attention at renewal.

Across six employees with chronic low back pain, the cumulative annual cost is $42,000. Across three employees progressing toward knee replacement and two toward shoulder surgery, the claims trajectory is worse. In five years, the plan will pay $200,000 in surgical claims that were visible in the imaging and injection patterns years earlier. No one was watching.

Musculoskeletal conditions affect more than half of U.S. working-age adults. They cost the U.S. healthcare system an estimated $420 billion annually according to Evernorth, more than diabetes, cardiovascular disease, or any other single chronic condition category. The Business Group on Health’s 2025 employer survey found that cancer and MSK conditions remained the top two cost drivers for large employers, with three out of four employers ranking MSK among their top two health cost categories. MSK conditions are the leading driver of healthcare utilization by volume. They rarely trigger stop loss. Their cost operates through frequency and compounding. MSK is the cost driver doing the most cumulative damage without generating any alarm.

The Volume and Cost Profile

#

MSK conditions include low back pain, osteoarthritis, degenerative disc disease, rotator cuff injuries, carpal tunnel syndrome, and related disorders of bones, muscles, joints, and connective tissue. The category generates more healthcare encounters than any other condition group in working-age populations. UnitedHealthcare’s analysis of its book of business documented MSK costs to employers at $40.51 per member per month, a figure that reflects the high frequency and broad distribution of MSK utilization across covered populations.

Evernorth data shows that wear-and-tear conditions, which include strains, sprains, ligament tears, disc herniations, and degenerative joint disease, account for 63.5 percent of all MSK-related utilization and spending. The remaining share is split between major trauma (fractures and crush injuries) and autoimmune conditions (rheumatoid arthritis and related disorders).

The per-episode costs are moderate. A physical therapy evaluation runs $150 to $250. A PT session runs $125 to $200. An orthopedic consultation runs $300 to $500. An MRI of the lumbar spine runs $800 to $2,500 depending on facility and market. A cortisone injection runs $150 to $500. An epidural steroid injection runs $2,000 to $4,000. A knee arthroscopy runs $8,000 to $15,000. A total knee replacement runs $30,000 to $50,000. A lumbar fusion runs $50,000 to $150,000.

Estimates place MSK costs at approximately 15 percent of total employer medical spending. For a 25-person plan with $300,000 in annual claims, MSK conditions generate $45,000 to $60,000 in annual spending distributed across many members in small increments. No individual claim draws attention. The aggregate is substantial.

The cost distribution differs from every other category in this series. Specialty drugs (LFP-09.01) concentrate cost in a few members at very high per-member expense. Pregnancy (LFP-09.02) concentrates cost in a few events with high variance. MSK distributes cost across many members at moderate per-member expense. The aggregate is large, but the distribution renders it invisible to standard reporting.

The Compounding Trajectory

#

The escalation pathway from conservative treatment through interventional procedures to surgery is clinically documented and visible in claims data for anyone tracking it.

A typical trajectory for chronic low back pain: the member sees a primary care physician. The physician prescribes NSAIDs and orders imaging. The MRI shows degenerative changes. The member is referred to physical therapy. After six weeks with partial improvement, the member is referred to a spine specialist. The specialist orders additional imaging and recommends epidural steroid injections. After two injection series with temporary relief, the member is evaluated for surgical options. If surgery proceeds, a lumbar fusion generates $80,000 to $150,000 in claims.

The cumulative pre-surgical cost: primary care visits ($500), MRI ($1,500), physical therapy ($2,400), specialist visits ($800), additional imaging ($1,000), two epidural injection series ($6,000). Total pre-surgical spend: approximately $12,000 over 12 to 24 months in small increments that no one tracked as a trajectory.

The pattern repeats across MSK categories. Knee osteoarthritis progresses from physician visits through imaging through injections through arthroscopy through total knee replacement ($30,000 to $50,000). Rotator cuff injury progresses similarly through imaging, therapy, and injections to surgical repair ($15,000 to $30,000). Each trajectory generates $10,000 to $25,000 in pre-surgical claims before the high-cost event that finally appears in plan reporting.

The stop loss interaction is the critical distinction between MSK costs and the other cost drivers in this series. Specialty drugs (LFP-09.01) breach specific stop loss attachment points. Pregnancy with NICU (LFP-09.02) breaches specific stop loss. Cell and gene therapies (LFP-09.05) overwhelm both specific and aggregate layers. MSK costs do none of these things. A member generating $8,000 in MSK claims across a plan year is nowhere near a $75,000 specific attachment point. Six members generating a combined $48,000 in MSK claims are invisible at the individual level. The aggregate impact compresses the claims fund without triggering any stop loss mechanism. The stop loss architecture protects against catastrophic individual claims. It has no mechanism for addressing the slow erosion of the claims fund by high-frequency, moderate-cost conditions distributed across multiple members. MSK is the category most precisely calibrated to avoid every alarm in the system.

Sun Life’s 2025 annual high-cost claim analysis ranked orthopedics and MSK conditions as the third leading cost driver, with total spending of $1.18 billion for the reporting period. The Lown Institute estimated that U.S. hospitals performed 200,000 unnecessary back surgeries over three years on Medicare beneficiaries alone. Published research suggests that 35 percent of all MSK surgeries are not evidence-based or necessary. Six percent of members drive 85 percent of MSK costs according to one claims analysis, a concentration ratio that suggests targeted intervention could produce disproportionate savings.

Why Plans Ignore It

#

Three factors explain why MSK costs escape plan sponsor attention while generating substantial aggregate expense.

Individual claims fall below reporting thresholds. Most TPA reporting highlights claims above $10,000 or $25,000 as high-cost claimants requiring attention. An $1,800 PT course, a $2,500 injection series, a $1,200 MRI each fall below any reasonable threshold. They blend into routine claims without triggering review. The member generating $8,000 in MSK claims across four episodes in a plan year does not appear on any high-cost report.

Aggregate MSK spend is not broken out in standard reporting. Most employer plan reports show spending by service category: inpatient, outpatient, physician, pharmacy. MSK claims appear as outpatient imaging, outpatient surgery, and professional claims. They are not flagged as MSK-related. The employer cannot see that 15 percent of their claims represent a trajectory toward joint replacements and spine surgeries.

The compounding trajectory spans multiple plan years. The $12,000 in pre-surgical MSK spending for one member may accumulate over three plan years. The member’s name never appears on any high-cost report in any single year. The surgical claim that arrives in year four looks like a discrete event rather than the culmination of a visible trajectory. In a level funded plan that renews annually, the plan sponsor sees a spike in claims cost without recognizing the years of conservative treatment that predicted it.

TPAs with real-time claims intelligence can identify members on escalating MSK trajectories. Rising imaging frequency, specialist referral patterns, and injection utilization signal progression toward surgical intervention. Most small group TPAs do not have this analytical capability. The claims are processed and paid. The pattern is not identified. The surgical claim arrives.

The Blue-Collar Amplifier

#

MSK prevalence varies by occupation. Physically demanding work increases injury rates, accelerates joint degeneration, and drives higher baseline MSK utilization. The industries where level funded adoption is growing overlap with the industries where MSK prevalence is highest.

Construction workers, landscaping crews, manufacturing employees, skilled tradespeople, warehouse workers, and home health aides all carry elevated MSK risk compared to office workers. The CDC National Health Interview Survey documents MSK condition prevalence by occupation category, showing rates 50 to 100 percent higher for physically demanding occupations than for sedentary work.

The blue-collar small employer with a level funded plan faces higher baseline MSK cost exposure than a professional services firm. A 20-person construction company has fundamentally different MSK economics than a 20-person consulting firm. The stop loss underwriting may partially reflect this through industry rating factors. The plan design rarely does. The employer is not aware of the differential exposure. The broker presenting the level funded option may not flag the MSK risk embedded in the employer’s industry profile.

The overlap matters at the market level. Level funded adoption is growing in construction, landscaping, hospitality, home health, and skilled trades. These are the industries with the highest MSK prevalence. The MSK cost burden in the level funded book of business is not the national average. It is weighted toward the high end of the prevalence distribution.

The cost management opportunity is documented. Virtual physical therapy programs from vendors including Hinge Health and Sword Health provide evidence-based MSK care at lower cost than in-person PT, with studies documenting comparable outcomes and higher completion rates. The cost per episode is typically 30 to 50 percent lower than in-person PT at commercial reimbursement rates. Evernorth’s research found that seeking behavioral health treatment for comorbid anxiety and depression alongside MSK care decreased the need for surgery, saving approximately $460 per patient per month.

Surgical second opinion programs reduce unnecessary surgery and steer appropriate cases to higher-quality facilities. Avoiding unnecessary MSK surgery at the rate documented by the Lown Institute would save billions annually across the employer market. Facility steering to independent ambulatory surgery centers, which price orthopedic procedures 30 to 50 percent below hospital-owned facilities, produces immediate per-case savings of $10,000 to $40,000 for joint replacements and spine procedures.

Each intervention requires TPA-level infrastructure to identify candidates through claims pattern analysis, coordinate care pathways, and monitor outcomes. Series 10 examines MSK cost management programs in operational detail. The point here is that MSK is the highest-volume, most compounding, and most overlooked cost category in small group plans, and the interventions that address it are among the most accessible for TPAs willing to build the infrastructure.